advertisement
11.4 Prostaglandins (145)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Pillunat LE
Clinical Ophthalmology 2016; 10: 1759-1765
70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Konstas AG
Advances in Therapy 2017; 34: 221-235
69963 Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?
Kara C
International Ophthalmology 2017; 37: 619-626
70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Wadhwani M
Journal of Current Glaucoma Practice 2016; 10: 49-55
69964 Structural features of subtype-selective EP receptor modulators
Markovič T
Drug Discovery Today 2017; 22: 57-71
70466 Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Garcia GA
Clinical Ophthalmology 2016; 10: 2035-2050
70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Mlčáková E
Česka a Slovenska Oftalmologie 2016; 72: 120-127
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Miller Ellis E
British Journal of Ophthalmology 2017; 101: 796-800
69977 The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction
Mocan MC
Journal of Glaucoma 2016; 25: 770-774
70795 Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study
Moschos MM
Drug design, development and therapy 2016; 10: 3977-3981
70467 Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
García-Feijoo J
Clinical Ophthalmology 2016; 10: 2085-2091
70173 Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
Ikeda Y
Clinical Ophthalmology 2016; 10: 1633-1637
70879 Intraocular Pressure-Lowering Effect of Latanoprost Is Hampered by Defective Cervical Lymphatic Drainage
Kim YK
PLoS ONE 2017; 12: e0169683
70100 Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study
Denis P
Journal Français d'Ophtalmologie 2016; 39: 622-630
70792 Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: a Randomized Trial
Barnebey HS
American Journal of Ophthalmology 2017; 176: 61-69
70222 Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
Chen YY
BMC Ophthalmology 2016; 16: 162
70577 The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection
Yamamoto K
Journal of Neurochemistry 2017; 140: 495-508
70252 Primary open-angle glaucoma
Weinreb RN
Nature reviews. Disease primers 2016; 2: 16067
70655 Structural and Histologic Eyelid Changes Associated with 6 Months of Topical Bimatoprost in the Rabbit
Kent TL
Journal of Glaucoma 2017; 26: 253-257
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of Latanoprost
Yoo R
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
70587 Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma
Cui XJ
Journal of Clinical Pharmacy and Therapeutics 2017; 42: 87-92
70254 Mitochondrial pathogenic mechanism and degradation in optineurin E50K mutation-mediated retinal ganglion cell degeneration
Shim MS
Scientific reports 2016; 6: 33830
70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Lewis RA
American Journal of Ophthalmology 2017; 175: 137-147
70513 New classes of glaucoma medications
Schehlein EM
Current Opinions in Ophthalmology 2017; 28: 161-168
70256 Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration
Kimura A
International journal of molecular sciences 2016; 17:
